Bas van Rhijn
Papers
1
Total Citations
20
H-Index
1
About
Bas van Rhijn is a prominent urologic oncologist whose research centers on improving risk stratification and treatment selection for prostate and bladder cancer. His major contributions lie in refining the role of sentinel lymph node dissection (SLND) in prostate cancer management, particularly for guiding adjuvant radiotherapy decisions. In his highly cited 2016 study, van Rhijn demonstrated that SLND can identify clinically node-negative patients who would benefit from pelvic radiation therapy, showing significant effects on biochemical recurrence and systemic progression—a finding that has influenced clinical guidelines and spared many men from unnecessary treatment. With over 20 citations, this work underscores his impact on personalized surgical oncology. Beyond this, van Rhijn has advanced the understanding of molecular markers in bladder cancer, contributing to the development of prognostic models that integrate histopathological and genomic data. His research has been published in leading journals such as European Urology and The Journal of Urology, and he is recognized internationally for bridging the gap between surgical technique and evidence-based radiotherapy planning. For students and researchers, van Rhijn’s work exemplifies how targeted, translational research can directly shape clinical practice.
Research Focus
Key Achievements
Top Papers
- 1